Simultaneously, in the MR analysis using the outcome data obtained from the UK Biobank, the IVW analysis predicted that proheparin-binding EGF (proHB-EGF constipation: OR = 0.999, 95%CI: 95% CI: 0.998–1.000, and p = 0.038; secondary constipation: OR = 0.999, 95%CI: 95% CI: 0.997–1.000, and p = 0.046), platelet-derived growth factor AA (PDGF-AA; OR = 0.999, 95%CI: 95% CI: 0.998–1.000, and p = 0.039), and vascular endothelial growth factor121 (VEGF121; OR = 0.999, 95%CI: 95% CI: 0.998–1.000, and p = 0.008) levels were inversely associated with constipation. Here, EGF is linked to constipation disorder.